Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma - 08/11/12
Corresponding author: Tel.: 86-451-86605575; fax: +86-451-86296673Abstract |
Background |
The purpose of this study was to determine whether lysosome-associated protein transmembrane-4 beta (LAPTM4B) overexpression is associated with the prognosis in patients with colorectal cancer.
Methods |
LAPTM4B expression was evaluated in colorectal cancer patients by Western blot analysis and immunohistochemistry. Univariate and multivariate analyses were performed to determine the association between LAPTM4B expression and prognosis.
Results |
Among the 136 patients with colorectal cancer, 51 patients had low LAPTM4B expression, and 85 patients had high LAPTM4B expression. The sensitivity and specificity of LAPTM4B overexpression were 62.5% and 100%, respectively. The 5-year overall survival (OS) rates for patients with high and low LAPTM4B expression were 37.38% and 98.04%, respectively (hazard ratio = 22.774; 95% confidence interval [CI], 5.287–98.091; P < .0001). The 5-year disease-free survival rate was 21.15% for patients in the high-expression group and 91.82% for patients in the low-expression group (hazard ratio = 11.674; 95% CI, 3.562–38.263; P < .0001).
Conclusions |
LAPTM4B overexpression is an independent factor in colorectal cancer prognosis, and it may be an important potential biomarker.
Le texte complet de cet article est disponible en PDF.Keywords : LAPTM4B, Colorectal cancer, Survival, Western blot, Immunohistochemistry
Plan
Vol 204 - N° 5
P. 677-683 - novembre 2012 Retour au numéro
Article précédent
- Management of colorectal anastomotic leakage: differences between salvage and anastomotic takedown
- Domenico Fraccalvieri, Sebastiano Biondo, Jose Saez, Monica Millan, Esther Kreisler, Thomas Golda, Ricardo Frago, Bernat Miguel
- Long-term results and quality of life in patients treated with hemorrhoidectomy using two different techniques: Ligasure versus transanal hemorrhoidal dearterialization
- Nicola Zampieri, Roberto Castellani, Remo Andreoli, Andrea Geccherle
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?